N

NewLimit

Develops epigenetic medicines to extend healthspan

Senior Scientist

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeSan Bruno, CA, USA$130k - $180k /yrIn-person

About the Job

Requirements

  • Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
  • Experience with primary cell isolation and functional characterization
  • Experience working with mouse models (e.g. kidney, cardiovascular, or cognitive disease models)
  • Experience with transgenic manipulation of primary cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)

Responsibilities

  • Develop functional assays and pre-clinical models to measure endothelial cell function
  • Collaborate with our Functional Genomics and Predictive Modeling teams to test reprogramming hypotheses at scale
  • Measure the impact of mRNA reprogramming medicines on endothelial cell function
  • Engineer in vivo nucleic acid delivery methods for endothelial cells
  • Analyze and interpret experimental data to drive pre-clinical decision making

Desired Qualifications

  • History of contributing to a drug development program at the pre-clinical or clinical development stage
  • Experience leading the design and execution of pre-clinical studies in mouse models
  • Experience with single cell genomics methods
  • Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)

About the Company

NewLimit

Develops epigenetic medicines to extend healthspan

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company size
51-200
Company stage
Series C
Total funding
$650M
Headquarters
South San Francisco, CA
Founded
2022

Recently Posted Jobs

Explore more opportunities at NewLimit

See more jobs